AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Oxybutynin Chloride Betters Rival In New Study.
2001 MAY 24 - (NewsRx Network) -- Results of a Phase IV clinical study evaluating the two leading medications for the treatment of overactive bladder were presented at the American College of Obstetricians and Gynecologists' (ACOG) 50th Annual Clinical Meeting.
The findings of the "Overactive Bladder: Judging Effective Control and Treatment" (OBJECT) study showed that patients suffering from overactive bladder experienced a significant reduction in symptoms, including the most troublesome - urge incontinence - when treated with extended-release oxybutynin chloride (Ditropan [XL.sup.R]) as compared to patients treated with tolterodine tartrate ([Detrol.sup.R]).
"The OBJECT study was a very well-designed investigation comparing the two drugs that are most widely prescribed in the United States for patients suffering from symptoms of overactive bladder," said presenter and study investigator Peter K. Sand, MD, director, Evanston Continence Center at Evanston Northwestern Healthcare and associate professor, Northwestern University Medical School, Illinois. "The results demonstrated superior efficacy with Ditropan XL in treating the problems associated with an overactive bladder, providing physicians with valuable knowledge in treating patients with the most effective medication available."
Overactive bladder affects approximately 17 million Americans, making it more prevalent than many commonly discussed conditions, such as diabetes (seven million) and Alzheimer's disease (four million). With symptoms of urinary urge incontinence, involuntary loss of bladder control; urgency, urgent need to urinate; and urinating more than eight times a day (micturition frequency), overactive bladder is one of the most under-diagnosed and under-treated conditions in the United States. In fact, fewer than 20% of sufferers actually talk to their physician about symptoms.
OBJECT is the first study to compare the efficacy and tolerability of Ditropan XL and Detrol. Study results showed statistically significant reductions in the number of urge and total incontinence episodes and in micturition frequency from baseline in both treatment groups (p[less than]0.001). Ditropan XL proved to be significantly more effective than Detrol in all study end points: urge incontinence (p=0.031), ...
- ALZA's Ditropan XL Approved for Treatment of Overactive Bladder.
- Press release article from: PR Newswire December 17, 1998 700+ words
...only once-a-day treatment for overactive bladder. Ditropan(R) XL provides control of overactive bladder for many patients -- treating...oxybutynin in the treatment of overactive bladder." An estimated 17 million Americans...
- Ditropan XL a Significant Advance in Treating Urge Incontinence; New Delivery...
- Press release article from: PR Newswire July 17, 2001 700+ words
...who were treated with Ditropan XL (extended-release...OBJECT Study (OBJECT - Overactive Bladder: Judging Effective...controlled trial comparing Ditropan XL to the other leading treatment for overactive bladder, Detrol (tolterodine...
- Ditropan XL Is Significant Advancement in Treatment of Urinary Incontinence.
- Press release article from: PR Newswire May 16, 2001 700+ words
...medications for the treatment of overactive bladder, Ditropan XL (extended- release oxybutynin...Gynecologists in Chicago (OBJECT - Overactive Bladder: Judging Effective Control...They then received either Ditropan XL once a day in the morning...
- IMPAX Comments on Alza's Lawsuit Related to Generic Version Of Ditropan XL.
- Press release article from: Business Wire September 9, 2003 700+ words
...generic version of Ditropan XL (Oxybutynin Chloride) Tablets, 15 mg. Ditropan XL Tablets are used for the treatment of overactive bladder with symptoms of urge...U.S. sales of Ditropan XL Tablets, 15 mg were...
- ALZA Announces Expansion of Ditropan XL(R) Promotion to Primary Care Audience...
- Press release article from: PR Newswire January 9, 2001 700+ words
...currently co-promoting Ditropan XL(R), the total number...dedicated to promoting Ditropan XL(R) will increase...representatives promoting Ditropan XL(R), allowing even...reach the undertreated overactive bladder marketplace." The...
- ALZA Corporation to Appeal U.S. District Court Decision on DITROPAN XL(R)...
- Press release article from: PR Newswire September 28, 2005 700+ words
...that the patent on DITROPAN XL is invalid and that...Pharmaceutical, Inc. markets DITROPAN XL in the U.S. and...the patent owner. DITROPAN XL is the first once...treatment approved for overactive bladder. The suit was initiated...
- Incontinence Drug.(Alza Corp.'s Ditropan XL)
- Magazine article from: Chain Drug Review January 18, 1999 700+ words
PALO ALTO, Calif. -- Alza Corp.'s Ditropan XL has been approved for the treatment of overactive bladder. It is the first once-a-day therapy to control the symptoms of urge incontinence.
- ALZA ANNOUNCES UNITED KINGDOM APPROVAL OF ONCE-DAILY DITROPAN XL.
- Press release article from: PR Newswire June 19, 2000 700+ words
...XL is indicated for the once-a-day treatment of overactive bladder, a chronic condition characterised by symptoms of urge...February 1999 and has captured 24 percent of the market for overactive bladder treatments. Under the terms of its agreement with ALZA...
Source: HighBeam Research, Oxybutynin Chloride Betters Rival In New Study.